Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 15;13(8):770.
doi: 10.3390/antibiotics13080770.

Cefiderocol-Based Regimen for Acinetobacter NDM-1 Outbreak

Giovanna Travi  1 , Francesco Peracchi  1   2 , Marco Merli  1 , Noemi Lo Re  3 , Elisa Matarazzo  4 , Livia Tartaglione  4 , Alessandra Bielli  4 , Giorgia Casalicchio  4 , Fulvio Crippa  1 , Chiara S Vismara  4 , Massimo Puoti  1   2
Affiliations

Cefiderocol-Based Regimen for Acinetobacter NDM-1 Outbreak

Giovanna Travi et al. Antibiotics (Basel). .

Abstract

Variable outcomes have been reported with cefiderocol in infections due to carbapenem-resistant Acinetobacter baumannii (CRAB). Nonetheless, it may be the only option for metallo-beta-lactamase-producing strains. We describe an outbreak of NDM-CRAB infections treated with cefiderocol. Thirty-eight patients were colonized and/or infected. Thirteen patients developed a systemic infection. A clinical cure was achieved in 10 (83%) patients, one VAP and 9 BSIs, at day 7. In vitro, the activity of cefiderocol does not appear to match in vivo effectiveness using currently available commercial tests. Despite high clinical cures, overall mortality remains high in severely ill patients. Cefiderocol may be considered in this specific setting, though the implementation of susceptibility tests and infection control measures is mandatory.

Keywords: Acinetobacter baumannii complex; NDM; cefiderocol; colistin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Wong D., Nielsen T.B., Bonomo R.A., Pantapalangkoor P., Luna B., Spellberg B. Clinical and pathophysiological overview of Acinetobacter infections: A century of challenges. Clin. Microbiol. Rev. 2017;30:409–447. doi: 10.1128/CMR.00058-16. - DOI - PMC - PubMed
    1. Harding C.M., Hennon S.W., Feldman M.F. Nature Reviews Microbiology. Volume 16. Nature Publishing Group; London, UK: 2018. Uncovering the mechanisms of Acinetobacter baumannii virulence; pp. 91–102. - PMC - PubMed
    1. Bonnin R.A., Poirel L., Nordmann P. New Delhi metallo-β-lactamase-producing Acinetobacter baumannii: A novel paradigm for spreading antibiotic resistance genes. Future Microbiol. 2014;9:33–41. doi: 10.2217/fmb.13.69. - DOI - PubMed
    1. Revathi G., Siu L.K., Lu P.L., Huang L.Y. First report of NDM-1-producing Acinetobacter baumannii in East Africa. Int. J. Infect. Dis. 2013;17:e1255–e1258. doi: 10.1016/j.ijid.2013.07.016. - DOI - PubMed
    1. Jones L.S., Toleman M.A., Weeks J.L., Howe R.A., Walsh T.R., Kumarasamy K.K. Plasmid carriage of blaNDM-1in clinical Acinetobacter baumannii isolates from India. Antimicrob. Agents Chemother. 2014;58:4211–4213. doi: 10.1128/AAC.02500-14. - DOI - PMC - PubMed

LinkOut - more resources